Amanda Copeland

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

Anas Younes, Yasuhiro Oki, R. Gregory Bociek et al. · The Lancet Oncology · 2011 · 195 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

Anas Younes, Jesús G. Berdeja, Manish R. Patel et al. · The Lancet Oncology · 2016 · 187 citations

Medicine, Oncology, Pharmacology +15

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

Anas Younes, Stella Kim, Jorge Romaguera et al. · Journal of Clinical Oncology · 2012 · 167 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +15

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

Anas Younes, Jorge Romaguera, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2012 · 139 citations

Medicine, Oncology, Pharmacology +13

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Yasuhiro Oki, Daniela Buglio, Michelle A. Fanale et al. · Clinical Cancer Research · 2013 · 110 citations · Full text

Medicine, Oncology, Pharmacology +17